Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer

Psycho-Oncology

Volumn 17, Issue 2, 2008, Pages 154-160

  Okamura, Masako ^a   Akizuki, Nobuya ^b   Nakano, Tomohito ^a   Shimizu, Ken ^a   Ito, Tatsuhiko ^b   Akechi, Tatsuo ^c   Uchitomi, Yosuke ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Advanced cancer; Algorithm; Antidepressant; Clinical experience; Major depressive disorder

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOMIPRAMINE; METHYLPHENIDATE; MIANSERIN; MILNACIPRAN; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ADVANCED CANCER; AGED; ALGORITHM; ANXIETY; ARTICLE; CLINICAL PROTOCOL; DELIRIUM; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; EXPERIENCE; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PROGNOSIS;

ADULT; AGED; ALGORITHMS; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CLOMIPRAMINE; DEPRESSIVE DISORDER, MAJOR; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 39549088291     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1213     Document Type: Article

References (35)

1. Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2005;49:124-138.
2. Hotopf M, Chidgey J, Addington-Hall J, Ly KL. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 2002; 16:81-97.
3. Grassi L, Indelli M, Marzola M et al. Depressive symptoms and quality of life in home-care-assisted cancer patients. J Pain Symptom Manage 1996;12: 300-307.
4. Okamura M, Yamawaki S, Akechi T, Taniguchi K, Uchitomi Y. Psychiatric disorders following first breast cancer recurrence: prevalence, associated factors and relationship to quality of life. Jpn J Clin Oncol 2005;35:302-309.
5. Cherny NI, Coyle N, Foley KM. Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 1994;10:57-70.
6. Breitbart W, Rosenfeld B, Pessin H et al. Depression hoplessness, and desire for hastened death in terminally ill patients with cancer. J Am Med Assoc 2000;284: 2907-2911.
7. Chochinov HM, Wilson KG, Enns M et al. Desire for death in the terminally ill. Am J Psychiatry 1995;152:1185-1191.
8. Henriksson MM, Isometsa ET, Hietanen PS, Aro HM, Lonnqvist JK. Mental disorders in cancer suicides. J Affect Disord 1995; 36:11-20.
9. Cassileth BR, Lusk EJ, Strouse TB, Miller DS, Brown LL, Cross PA. A psychological analysis of cancer patients and their next-of-kin. Cancer 1985;55:72-76.
10. Conill C, Verger E, Henriquez I et al. Symptom prevalence in the last week of life. J Pain Symptom Manage 1997;14:328-331.
11. Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 1996;12:3-10.
12. Ripamonti C. Management of bowel obstruction in advanced cancer patients. J Pain Symptom Manage 1994;9:193-200.
13. Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand 1985;72:85-92.
14. Fisch MJ, Loehrer PJ, Kristeller J et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003;21:1937-1943.
15. Heeringen KV, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 1996;169:440-443.
16. Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-Oncology 1998;7:291-300.
17. Morrow GR, Hickok JT, Roscoe JA et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:4635-4641.
18. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001;70:1-10.
19. Razavi D, Allilaire JF, Smith M et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996;94:205-210.
20. Roscoe JA, Morrow GR, Hickok JT et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005; 89:243-249.
21. Gilbert DA, Altshuler KZ, Rago WV et al. Texas medication algorithm project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-351.
22. Chochinov HM. Depression in cancer patients. Lancet Oncol 2001; 2:499-505.
23. Akizuki N, Akechi T, Nakano T, Okamura M, Uchitomi Y. Major depression in advanced cancer patients. In Pharmacological Treatment Algorithms for Affective Disorders, Motohashi N (ed.). Jiho: Tokyo, 2003; 83-99.
24. Akizuki N, Okamura H, Akechi T et al. Clinical experience of the pharmacological treatment algorithm for major depression in advanced cancer patients: preliminary study. Int J Psychiatry Clin Pract 2002; 6:83-89.
25. Wilson KG, Chochinov HM, Faye BJd, Breitbart W. Diagnosis and Management of Depression in Palliative Care. In Handbook of Psychiatry in Palliative Medicine, Chochinov HM, Breitbart W (eds). Oxford: New York, 2000; 25-49.
26. Lawlor PG, Gagnon B, Mancini IL et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000;160:786-794.
27. Moukaddam NJ, Hirschfeld RM. Intravenous antidepressants: a review. Depress Anxiety 2004;19:1-9.
28. Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord 2001;65:173-177.
29. Block SD. Assessing and managing depression in the terminally ill patient. Ann Intern Med 2000;132:209-218.
30. Homsi J, Walsh D, Nelson KA, LeGrand S, Davis M. Methylphenidate for depression in hospice practice: a case series. Am J Hosp Palliat Care 2000;17:393-398.
31. Kugaya A, Akechi T, Nakano T, Okamura H, Shima Y, Uchitomi Y. Successful antidepressant treatment for five terminally ill cancer patients with major depression, suicidal ideation and desire for death. Support Care Cancer 1999;7:432-436.
32. Lloyd-Williams M. Difficulties in diagnosing and treating depression in the terminally ill cancer patient. Postgrad Med J 2000; 76:555-558.
33. Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998;16:193-198.
34. Stiefel F, Die Trill M, Berney A, Olarte JM, Razavi D. Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care. Support Care Cancer 2001; 9:477-488.
35. Degner D, Grohmann R, Kropp S et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004;37(Suppl 1):S39-S45.